Filing Flows › TScan Therapeutics (TCRX) › Q1 2026 › vs Q4 2025
TScan Therapeutics (TCRX) Q1 2026 vs Q4 2025 (quarter over quarter)
TScan Therapeutics's revenue fell $1.6M (-62%) from $2.6M in Q4 2025 to $982K in Q1 2026.
TScan Therapeutics, Q1 2026: revenue $982K (-55% year over year), net loss $28.7M, operating cash flow −$24.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $982K | $2.6M | −$1.6M | -62% |
| Other income, net | $473K | $881K | −$408K | -46% |
| Net loss | $28.7M | $23.0M | $5.7M | +25% |
| Costs & expenses | $30.1M | $26.4M | $3.7M | +14% |
| Operating costs | $30.1M | $26.4M | $3.7M | +14% |
| Research & development | $21.9M | $20.0M | $1.9M | +9% |
| General & admin | $8.2M | $6.4M | $1.8M | +29% |
| Operating cash sources | $28.7M | $23.0M | $5.7M | +25% |
| Depreciation | $693K | $723K | −$30K | -4% |
| Share-based compensation | $2.5M | $2.0M | $457K | +23% |
| Working capital & other | $1.2M | −$11.8M | $13.0M | — |
| Cash used in operations | $24.3M | $32.0M | −$7.7M | -24% |
| Net loss absorbed | $28.7M | $23.0M | $5.7M | +25% |
Questions
How much did TScan Therapeutics's revenue grow quarter over quarter in Q1 2026?
TScan Therapeutics's revenue fell $1.6M (-62%) from $2.6M in Q4 2025 to $982K in Q1 2026.